Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Max Bayer

Pharma Reporter

A proposal by HHS Secretary Robert F. Kennedy Jr. to change the approval standard of new vaccines shouldn’t affect BioNTech’s Covid-19 franchise, the company told …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Bristol Myers to lay off over 500 workers in New Jersey

Early bits of in vivo CAR-T human data emerge from biotech trials in China

PTC's Huntington’s study succeeds, but accelerated approval uncertain

Recursion cuts nearly half of its pipeline, including its most advanced program

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

Pharma Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact